title: The effects of rosiglitazione on renal artery endothelium in diabetic rats.
abstract: BACKGROUND
  Macrovascular disease is a common complication of Diabetes Mellitus (DM). Study of renal artery endothelium may serve as a surrogate for cardiovascular and renal vascular disease.
  
  
  OBJECTIVE
  This study is to elucidate (1) how about the changes of renal endothelial ultrastructures it is in different time of diabetes animals (2) Whether PPARgamma ligand (such as rosiglitazone: ROS) could improve endothelium destruction in diabetes.
  
  
  METHODS
  Streptozoticin (STZ) induced diabetic rats were stratified by age groups from 6 to 10 weeks of age and were paired with age-matched control non-diabetic rats. Further, another group of diabetic rats were treated with ROS and matched with non-treated diabetic rats.
  
  
  RESULTS
  The renal artery endothelium of diabetic rats was partially coarse, distended, cracked and destroyed. The Vascular Endothelial Structure Score (VESS) was 34.5 in diabetic rats compared with non-diabetic control male rats (P=0.001). The older rats demonstrated more endothelial wall damage, more pronounced in male rats. Compared with non-treated control diabetic rats, ROS prevented diabetic endothelial damage (VESS=4.6, P=0.001).
  
  
  CONCLUSIONS
  Renal artery endothelium damage in STZ induced diabetic rats was significantly attenuated by rosiglitazone.
authors.affiliation: Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital Affiliated Shanghai Jiaotong University School of Medicine, Shanghai, China. luyingli2008@126.com
authors.forename: Y L
authors.initials: YL
authors.lastname: Lu
authors.forename: Y M
authors.initials: YM
authors.lastname: Jimbu
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: J B
authors.initials: JB
authors.lastname: Zhao
authors.forename: T T
authors.initials: TT
authors.lastname: Ye
authors.forename: H
authors.initials: H
authors.lastname: Yang
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology* / Q000648:ultrastructure; D005260:Female; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D012077:Renal Artery / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone